70 results on '"CTI Leusen"'
Search Results
2. Radiation response assessment of organoids derived from patients with pancreatic cancer
3. MUC13 negatively regulates tight junction proteins and intestinal epithelial barrier integrity via protein kinase C
4. From Evasion to Elimination: Enhancing IgA therapy through myeloid checkpoint inhibition
5. The Effect of Radiation Treatment of Solid Tumors on Neutrophil Infiltration and Function: A Systematic Review
6. Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0
7. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
8. Preclinical models and IgA anti-GD2 antibody therapy for neuroblastoma
9. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
10. IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset
11. Comprehensive single-cell genome analysis at nucleotide resolution using the PTA Analysis Toolbox
12. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial
13. Targeting the myeloid microenvironment in neuroblastoma
14. The Role of Cytokines in Neutrophil Development, Tissue Homing, Function and Plasticity in Health and Disease
15. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
16. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
17. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
18. Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains
19. Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses
20. Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody
21. Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
22. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
23. IgG Subclass-Dependent Pulmonary Antigen Retention during Acute IgG-Dependent Systemic Anaphylaxis in Mice
24. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB (R)
25. MutationalPatterns: the one stop shop for the analysis of mutational processes
26. Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort
27. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
28. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
29. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy
30. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
31. Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell
32. Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
33. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
34. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
35. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms
36. Synergestic Tumor-Killing Effect by Cross-Hybrid IgGA Fc
37. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
38. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
39. ARGX-117, a therapeutic complement inhibiting antibody targeting C2
40. Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent
41. IgA-mediated killing of tumor cells by neutrophils is enhanced by CD47–SIRPA checkpoint inhibition
42. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
43. Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV
44. gamma 9 delta 2T cell diversity and the receptor interface with tumor cells
45. Immune Effector Functions of Human IgG2 Antibodies against EGFR
46. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering
47. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma
48. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
49. Prediction of pre-eclampsia: review of reviews
50. Heparin Forms Polymers with Cell-free DNA Which Elongate Under Shear in Flowing Blood
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.